Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage
Condition(s):Heart Failure; Pulmonary HypertensionLast Updated:September 12, 2017Withdrawn
Hide Studies Not Open or Pending
Condition(s):Heart Failure; Pulmonary HypertensionLast Updated:September 12, 2017Withdrawn
Condition(s):Erectile DysfunctionLast Updated:September 23, 2019Completed
Condition(s):Obesity; Sexual DysfunctionLast Updated:October 26, 2016Completed
Condition(s):Erectile DysfunctionLast Updated:April 26, 2013Completed
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:February 28, 2020Completed
Condition(s):HealthyLast Updated:May 25, 2022Completed
Condition(s):Erectile Dysfunction; AndropauseLast Updated:October 24, 2016Unknown status
Condition(s):Erectile Dysfunction and Neutrophil Lymphocyte RatioLast Updated:July 20, 2022Not yet recruiting
Condition(s):Pulmonary Arterial HypertensionLast Updated:October 9, 2019Completed
Condition(s):Benign Prostatic HyperplasiaLast Updated:November 24, 2017Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.